← All stories
Markets
Moderna, Merck Revive mRNA Hopes With Melanoma Success
A personalized vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technol…
Covered by 1 outlet
All coverage · 1 article